RaySearch Laboratories AB (publ) (RAY_B) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to RACE Search presentation of the second quarter of 2026. My name is Carolina Strömlid and I'm head of Investor Relations. Today, our CEO and founder, Johan Löf, and our CFO, Nina Grönberg, will take you through the key highlights and financial results for the quarter. After the presentation, we will open up for questions. Simply raise your hand in teams if you would like to ask a question. And with that short introduction, I'll hand over to you, Johan. Thank you, Carolina, and welcome again, everyone. This is a summary of research as of today. We have four different software platforms, RayStation, which is a treatment planning system, RayCare, which is an oncology information system, RayIntelligence, an analytics platform, and RayCommand, which is a treatment control system. and they're all dedicated to improving cancer treatments. We have 472 employees of 41 different nationalities. We collaborate with 26 industrial partners and we have over 1,200 customers in 51 countries. But most importantly, our software has been used to treat over 11 million cancer patients. So this is the revenue development over a very long period of time. And the message here is that research has grown every year since 2008, except for the two pandemic years. Even though, as we can see in this diagram, the fluctuations between quarters can be quite significant. And you look at the last two quarters, we have had two quite significant week quarters but nevertheless we expect that this growth journey to continue. So a few words about Q2. So the weaker development in net sales and operating profit during the quarter was of course disappointing. It was primarily due to poor performance in the US where several deals were postponed compared to our expectations. Net sales decreased by 11% ...